STAT
OCTOBER 25, 2023
The other scenario involved treatments that were more expensive, but no more effective than alternatives, such as the Abraxane chemotherapy. The researchers examined Medicare beneficiaries who were diagnosed with cancer and received treatment from 2014 through 2019.
Express Pharma
APRIL 25, 2024
In 2014, the FDA approved the first (adenosine diphosphate-ribose) polymerase (PARP) inhibitor AstraZeneca /Merck’s Lynparza (olaparib) for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients who have received three or more prior lines of chemotherapy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
DECEMBER 12, 2024
This authorisation of the antibody drug conjugate Elahere provides a much needed clinically meaningful option for women living with this type of ovarian cancer, whose disease returns because they develop resistance to platinum-based chemotherapy regimens. Platinum resistance is often associated with low survival rates and outcomes.
pharmaphorum
AUGUST 4, 2021
The HDAC inhibitor was given an accelerated approval by the FDA as a second-line PTCL therapy on the strength of overall response data, but a phase 3 study comparing Istodax to first-line chemotherapy showed no improvement on progression-free survival (PFS).
pharmaphorum
NOVEMBER 29, 2022
At NeoImmuneTech, a Biotech company founded in Maryland, US, in 2014, the answer to this question looks straightforward: “We believe in incremental progress”, says Dr Se Hwan Yang, president and chief executive officer of the company. Dr Se Hwan Yang, PhD, President and Chief Executive Officer, founded NeoImmuneTech in January 2014.
pharmaphorum
MARCH 8, 2021
AZ is seeking to use Lynparza in patients who had also been previously treated with the chemotherapy drug docetaxel, but NICE has concluded that the application failed to provide evidence of the PARP inhibitor’s value compared to standard therapy.
pharmaphorum
NOVEMBER 5, 2020
First, it was testicular cancer, back in 1991, then I was diagnosed with liposarcoma in 2010, and pancreatic cancer in 2014.”. Robert decided to enrol on a clinical trial of chemotherapy plus high dose vitamin D at the University of Pennsylvania. The pancreatic cancer, however, was a “completely different ball game”. “At
Expert insights. Personalized for you.
345 
Let's personalize your content